Scottish Medicines Consortium accepts use of Kyntheum®▼ (brodalumab) for eligible patients with moderate-to-severe plaque psoriasis
The Scottish Medicines Consortium (SMC) has issued advice accepting brodalumab 210mg for restricted use within NHS Scotland. Following a successful resubmission, the SMC has accepted brodalumab for the treatment of moderate-to-severe plaque psoriasis in adult patients who have not responded to standard systemic therapies, or who are unable to take them.
This advice is contingent on the continued provision of a Patient Access Scheme (PAS), under which brodalumab is offered at a confidential discount to the NHS, or a list price that is equivalent or lower. Following this assessment, brodalumab will be available to appropriate patients on the NHS in Scotland.
“This decision from the SMC is significant news for people in Scotland living with psoriasis, an often misunderstood, lifelong and visible condition that can have a huge physical and emotional impact. Whilst many options are available, patients often have to try a number of different treatments during the course of their lifetime to improve their condition,” said Professor David Burden, Consultant Dermatologist at the University of Glasgow. “Brodalumab has a different way of working compared to other biologics currently available and so represents a further expansion of the treatment options available, offering greater choice for our patients.”
Dr Sathish Kolli, Medical Director at LEO Pharma UK/IE, added, “The Scottish Medicines Consortium’s advice is a significant step for us and it concludes our journey to make brodalumab accessible to all eligible patients within the UK, following the recent recommendation from the National Institute for Health and Care Excellence (NICE) for eligible adults with severe plaque psoriasis in England and Wales. As a company dedicated to addressing the significant unmet needs in dermatology, and bringing forward new developments, we are proud to have brought brodalumab to market.”
The full SMC advice is as follows:
ADVICE: following a resubmission
brodalumab (Kyntheum®) is accepted for restricted use within NHS Scotland.
Indication under review: for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.
Brodalumab was superior to placebo and to an alternative interleukin inhibitor at improving symptoms in adults with moderate to severe plaque psoriasis.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost- effectiveness of brodalumab. It is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.
For more information, please visit www.leo-pharma.co.uk
